Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio Inc (NY: ANVS )

9.090 -0.190 (-2.05%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio Inc

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – ANVS
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
ANVS CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Annovis Bio, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. 
Via The Motley Fool
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
ANNOVIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Annovis Bio, Inc. on Behalf of Annovis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
61 Biggest Movers From Yesterday
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.... 
Via Benzinga
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Annovis Bio, Inc.
From Kirby McInerney LLP
Via Business Wire
40 Stocks Moving In Monday's Mid-Day Session
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:... 
Via Benzinga
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business. 
Via The Motley Fool
ANVS Stock: The Alzheimer’s Drug News That Has Annovis Bio Plunging Today
Shares of ANVS stock are plummeting on Thursday after Annovis Bio reported weak results from two clinical trials for its leading drug. 
Via InvestorPlace
63 Biggest Movers From Friday
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the... 
Via Benzinga
Exposures Product Safety
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
70 Biggest Movers From Yesterday
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private... 
Via Benzinga
Mid-Day Market Update: LendingClub Surges Following Strong Q2 Results; Atreca Shares Plummet
Midway through trading Thursday, the Dow traded up 0.55% to 35,122.75 while the NASDAQ rose 0.47% to 14,831.28. The S&P also rose, gaining 0.61% to 4,427.36. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
44 Stocks Moving In Thursday's Mid-Day Session
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration approval for UroShield from TGA Australia.... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates
Following the market opening Thursday, the Dow traded up 0.44% to 35,085.92 while the NASDAQ rose 0.27% to 14,802.51. The S&P also rose, gaining 0.45% to 4,420.49. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday. 
Via Investor's Business Daily
28 Stocks Moving in Thursday's Pre-Market Session
Gainers LendingClub Corporation (NYSE: LC) shares rose 44.6% to $23.49 in pre-market trading after the company reported better-than-expected Q2 results and raised guidance. Acer... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell. 
Via Investor's Business Daily
Annovis Bio's Alzheimer's Candidate To Proceed Into Final Cohort Of Mid-Stage Study, Data Expected In 2022
Data Safety Monitoring Board (DSMB) has reviewed safety and tolerability data for Cohort 2 of Annovis Bio Inc's (NYSE: ANVS) Phase 2 Alzheimer's disease trial... 
Via Benzinga
Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks
Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it. 
Via The Motley Fool
Here's Why The Biotech Stocks You Bought Keep Going Down
Good news! There's a way to avoid this portfolio pain -- and it doesn't involve avoiding the whole sector. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.